1. Home
  2. MLYS vs LEG Comparison

MLYS vs LEG Comparison

Compare MLYS & LEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • LEG
  • Stock Information
  • Founded
  • MLYS 2019
  • LEG 1883
  • Country
  • MLYS United States
  • LEG United States
  • Employees
  • MLYS N/A
  • LEG N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • LEG Home Furnishings
  • Sector
  • MLYS Health Care
  • LEG Consumer Discretionary
  • Exchange
  • MLYS Nasdaq
  • LEG Nasdaq
  • Market Cap
  • MLYS 893.0M
  • LEG 885.3M
  • IPO Year
  • MLYS 2023
  • LEG N/A
  • Fundamental
  • Price
  • MLYS $15.14
  • LEG $9.39
  • Analyst Decision
  • MLYS Strong Buy
  • LEG Hold
  • Analyst Count
  • MLYS 3
  • LEG 4
  • Target Price
  • MLYS $33.00
  • LEG $10.50
  • AVG Volume (30 Days)
  • MLYS 679.3K
  • LEG 3.3M
  • Earning Date
  • MLYS 05-12-2025
  • LEG 04-28-2025
  • Dividend Yield
  • MLYS N/A
  • LEG 2.14%
  • EPS Growth
  • MLYS N/A
  • LEG N/A
  • EPS
  • MLYS N/A
  • LEG N/A
  • Revenue
  • MLYS N/A
  • LEG $4,308,800,000.00
  • Revenue This Year
  • MLYS N/A
  • LEG N/A
  • Revenue Next Year
  • MLYS N/A
  • LEG $1.12
  • P/E Ratio
  • MLYS N/A
  • LEG N/A
  • Revenue Growth
  • MLYS N/A
  • LEG N/A
  • 52 Week Low
  • MLYS $8.24
  • LEG $6.48
  • 52 Week High
  • MLYS $18.38
  • LEG $14.30
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 61.10
  • LEG 64.65
  • Support Level
  • MLYS $14.03
  • LEG $9.05
  • Resistance Level
  • MLYS $15.79
  • LEG $9.44
  • Average True Range (ATR)
  • MLYS 0.93
  • LEG 0.34
  • MACD
  • MLYS 0.16
  • LEG 0.18
  • Stochastic Oscillator
  • MLYS 92.27
  • LEG 80.60

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About LEG Leggett & Platt Incorporated

Leggett & Platt Inc designs and produces engineered components and products found in homes and automobiles. It operates its business through three segments namely Bedding Products, Specialized Products, and Furniture, Flooring, and Textile Products. It generates the majority of its revenue from Bedding Products. Serving a broad suite of customers around the world, Leggett & Platt's products include bedding components, automotive seat support, and lumbar systems, specialty bedding foam and private label finished mattresses, components for home furniture, and work furniture, flooring underlayment, adjustable beds, and various other products.

Share on Social Networks: